Nitric Oxide–cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension

Melanie Reinero, MSc¹, Maurice Beghetti, MD², Piergiorgio Tozzi, MD¹, Ludwig K. von Segesser, MD³, Michele Samaja, PhD⁴, and Giuseppina Milano, PhD¹

Abstract
Manipulation of nitric oxide (NO) may enable control of progression and treatment of pulmonary hypertension (PH). Several approaches may modulate the NO-cGMP pathway in vivo. Here, we investigate the effectiveness of 3 modulatory sites: (i) the amount of L-arginine; (ii) the size of plasma NO stores that stimulate soluble guanylate cyclase; (iii) the conversion of cGMP into inactive 5′-GMP, with respect to hypoxia, to test the effectiveness of the treatments with respect to hypoxia-induced PH. Male rats (n = 80; 10/group) maintained in normoxic (21% O₂) or hypoxic chambers (10% O₂) for 14 days were subdivided in 4 sub-groups: placebo, L-arginine (20 mg/ml), the NO donor molsidomine (15 mg/kg in drinking water), and phosphodiesterase-5 inhibitor sildenafil (1.4 mg/kg in 0.3 ml saline, i.p.). Hypoxia depressed homeostasis and increased erythropoiesis, heart and right ventricle hypertrophy, myocardial fibrosis and apoptosis inducing pulmonary remodeling. Stimulating anyone of the 3 mechanisms that enhance the NO-cGMP pathway helped rescuing the functional and morphological changes in the cardiopulmonary system leading to improvement, sometimes normalization, of the pressures. None of the treatments affected the observed parameters in normoxia. Thus, the 3 modulatory sites are essentially similar in enhancing the NO-cGMP pathway, thereby attenuating the hypoxia-related effects that lead to pulmonary hypertension.

Keywords
L-arginine, NO-donors, PDE5 inhibitors, NO-cGMP pathway, hypoxia, pulmonary hypertension

Introduction
Pharmacological modulation of nitric oxide (NO) is well-known to be an efficient way to regulate the progression of several cardiopulmonary diseases and to represent a potential therapeutic option. Many studies suggest that NO bioavailability is indeed reduced in patients and in rodent models of pulmonary vascular diseases, and that enhancement of the NO-cyclic guanosine monophosphate (cGMP) pathway (Figure 1) may represent an effective strategy for treatment.¹⁻⁴ NO is synthesized in endothelial cells from L-arginine (L-Arg) by endothelial NO synthase (eNOS).⁵ After its release in the circulation, it establishes an equilibrium with plasma nitrates and nitrites (NOx) and, to a minor extent, with circulating hemoglobin (Hb) to form nitrosylated Hb or nitrosothiolated Hb.⁶ Part of NO enters the smooth muscle cell, where it activates soluble guanylate cyclase (sGC) generating cGMP, which in turns activates protein kinase G that sequesters Ca²⁺ thereby favoring smooth muscle relaxation.⁷ Although controversial,⁸ the same mechanism in the myocytes might contribute to decrease muscle contractility thereby acting as a negative inotropic factor. The cellular level of cGMP is kept under the control of the activity of phosphodiesterase 5 (PDE5), which converts active cGMP in inactive 5′-GMP.

The mentioned chain of events may be modulated at 3 levels at least, by altering: (i) the amount of L-Arg entering the chain; (ii) the amount of NO in the plasma that can stimulate sGC; or (iii) the amount of cGMP that is inactivated to 5′-GMP by...
PDE5. Several drugs have been proposed to manipulate the NO-cGMP pathway activity through 3 broad approaches: i) by manipulating the level of L-Arg, ii) by increasing the amount of plasma NO, for example through the use of NO donors, and iii) by modulating the activity of PDE5, for example through the use of PDE5 inhibitors. The NO-cGMP pathway has become a therapeutic target and several treatments, as inhaled NO, administration of PDE5 inhibitors and soluble guanylates cyclase modulators, have been proposed to treat several cardiopulmonary diseases, such as pulmonary arterial hypertension (PAH, group 1 of PH) and neonatal respiratory diseases associated with PH.10 Although any one of the mentioned actions to exploit the NO-cGMP pathway-based therapies could be considered effective, in the clinical practice this does not occur, and a recent Cochrane survey shows that there is currently insufficient evidence to recommend NO donors, L-Arg or eNOS inhibitors in acute stroke, and only one drug, glyceryl trinitrate is able to give measurable clinical endpoints.11 Although inhaled NO is approved to treat certain types of PH and PDE5 inhibitors are approved in the treatment of PAH, the overlapping of several side reactions that eventually masks the final outcome also plays a role in this disappointing result.

The aim of this study is to investigate separately the effectiveness of the 3 modulations mentioned above with respect to a single cardiopulmonary stress, e.g. hypoxia, in order to understand how a single modulation affects the final outcome. To this purpose, here we examine the effects of manipulation of the NO pathway with regard to the chronic hypoxic cardiopulmonary system. It is widely appreciated that NO production is limited by insufficient supply of L-Arg. When administered in a variety of cardiovascular diseases, L-Arg, NO donors and PDE5 inhibition appear to reduce PH progression in hypoxic animals and chronic heart failure patients. Yet, studies that compare these strategies using the same methods, approaches, procedures and kinds of animals with the same PH severity have not yet been performed. Therefore, this study aims at supporting the paradigm that pulmonary hemodynamics and gas exchange efficiency may benefit from NO-based approaches in patients with PH.

Materials and Methods
Chronic Hypoxia and Experimental Groups
Adult male Sprague-Dawley rats (n = 80; 10/group; 200-250 g; Charles River, France) were randomly assigned to 1 of 4 treatments: Control (no treatment), L-Arg (20 mg/ml in drinking water), the NO-donor molsidomine (Mols, 0.1875 mg/ml in drinking water), and the PDE5 inhibitor sildenafil (Sild, 1.4 mg/kg in 0.3 ml saline, i.p.). In each group, rats were maintained either in normoxic (21% O2) or hypoxic chambers (10% O2) for 14 days.12,13 The chambers, built to accommodate 4 rats each, differed only for the gas mixture flowing through them. When the hypoxic chambers needed to be opened for
cleaning and monitoring, they were equipped with a compensation chamber flowed with the same gas mixture of the hypoxic chamber, thereby avoiding any contact of the rat with room air and its reoxygenation. Rats were treated with the assigned drug since day 0 of normoxia or hypoxia exposure. At day 15, rats were first transferred anaerobically to the compensation chamber, then anesthetized i.p. with a cocktail containing 10 mg/kg xylazine, 100 mg/kg ketasol and 1500 IU heparin within the compensation chamber at 10% O2, thus avoiding reoxygenation before sacrifice. In each subgroup, 2 subsets of rats were used, one for hemodynamic and morphological analyses, and one for tissue assays.

Animal experiments were performed according to the Swiss Federal guidelines (Ethical Principles and Guidelines for Experiments on Animals). The protocol was approved by the local Institutional Animal Committee (Service Vétérinaire Cantonal, Lausanne, Switzerland). All efforts were made to minimize animal suffering during the experiments.

Right Heart Catheterization
To examine PH development, we measured the RV systolic pressure (RVSP) and the RV contractility expressed as maximum rate of pressure development (dP/dt max). Briefly, a small traverse incision was made in the abdominal wall, the diaphragm was exposed and opened. A 24-gauge butterfly needle with tubing attached to a pressure catheter was inserted into the RV and pressure measurements were recorded with PowerLab (AD Instruments, Colorado Springs, CO).

Blood Collection and Analysis
At the end of the hemodynamic study, a blood sample was collected in heparinized syringes from the abdominal vein to measure Hb concentration, hematocrit and red blood cell count (Abbott Cell-dyn 3500 R System, Baar, Switzerland). The remaining sample was centrifuged for 15 min at 3000g. Plasma was stored at −80°C. For the measurements of NOx, we used the Nitric Oxide Colorimetric assay kit (Nitrate/Nitrite colorimetric Assay Kit, Cayman Chemical, No. 780001) following the manufacturer’s protocol.

Heart Morphology
The anesthetized animals were sacrificed by exsanguination, heart and lung were washed with PBS at 4°C, harvested and processed for analysis. The RV was separated from the left ventricle (LV) and septum (S), and all parts were weighed separately. The degree of RV hypertrophy was calculated as the RV/LV+S ratio.

The degree of cardiac fibrosis was determined by Sirius red staining. Briefly, 10 μm-thick paraffin-embedded tissue sections were deparaffinized, rehydrated and stained in iron hematoxylin for 10 min, followed by rinsing in water for 10 min. The slides were then stained in 0.1% (w/v) Sirius Red F3B (Sigma-Aldrich, Buchs SG, Switzerland) in saturated aqueous picric acid (Sigma-Aldrich, Buchs SG, Switzerland) for 1 h. Sections were washed twice in 0.5% v/v acetic acid, dehydrated rapidly 3 times in 100% alcohol, cleared in xylene and mounted using Merckoglas medium (Merck, Germany). Each section was photographed under a light microscope (Nikon Instruments Inc., Melville, NY, USA) at 10x magnification. At least 10 fields were randomly selected for each rat, each of which contains at least 6 vessels. Images were analyzed using Image software. The percentage collagen was calculated as fibrosis area/total area of the tissue section.

Pulmonary Vascular Remodeling
To determine the degree of muscularization in pulmonary arterioles, we used the technique described in Nydegger et al., which includes lung inflation with formalin, embedding in paraffin and sectioning (8-μm thickness). Samples were then blocked with goat serum and incubated with an antibody against smooth muscle α-actin (α-SMA 1:250, clone 1A4, Sigma-Aldrich), followed by incubation with goat anti-mouse IgG secondary antibody (1/500, DAKO). After developing with 3,3′-diaminobenzidine and counter staining with hematoxylin and eosin, transversal cut arterioles were counted (image analysis system Nikon eclipse 80i camera with NIH image software, Nikon Instruments Inc., Melville, NY, USA). Pulmonary arterial thickening was measured by calculating the percentual pulmonary artery thickness as described in the literature. We analyzed 10 vessels for each rat (n = 6/group) by double-blind morphological analysis.

cGMP and Caspase-3 Activity
We measured cGMP in frozen tissue that was homogenized at 4°C with 0.1 mol L−1 HCl (10% wet wt/vol) and centrifuged (2000 rpm for 10 min at 4°C). The measurement of cGMP was made by an immunoassay kit (Assay designs, Inc., MI). Caspase-3 activity was tested by the Caspase-3/CPP32 colorimetric assay kit (MBL). NOx was determined by the Nitric Oxide Colorimetric assay kit (Nitrate/Nitrite colorimetric Assay Kit, Cayman Chemical, No. 780001) following the manufacturer’s protocol.

Statistics
Data are expressed as box and whiskers plot following the Tukey method, with outliers plotted individually when present. To detect significant differences, we first ran ordinary 2-way ANOVA analysis. If significant, we proceeded to the multiple comparison tests. To test whether hypoxia has effect on the single treatments, we used the Sidak’s multiple comparison test (significant comparisons are marked as # in the figures). To detect whether treatments had an effect with respect to controls within normoxia and hypoxia, we used the Dunnett’s test (significant comparisons are marked as § in the figures). Analyses were performed using GraphPad Prism version 8, San Diego, California USA. The significance level was set at P = 0.05.
Results

None of the rats that entered this study (243.7 ± 1.4 g body weight, BW) died nor showed signs of discomfort. Unless otherwise stated, the treatments did not have remarkable effects in normoxia rats.

Systemic Changes: Homeostasis, Erythropoiesis, and Plasma NOx

Fourteen-day hypoxia depressed the BW gain and increased (Hb) concentration ([Hb]) (Figure 2A and B). Plasma NOx expresses the level of NO stores in blood (Figure 2C). As expected, both L-Arg and Mols increased plasma NOx in normoxia, as opposed to lack of effect of Sild, which affects the NO-cGMP pathway downstream.

The treatments in hypoxia did not substantially affect neither the BW gain nor [Hb], although Sild slightly improved the BW gain and Mols slightly increased [Hb]. L-Arg and Sild were unable to alter plasma NOx, but Mols further increased it by virtue of its NO-donor effect. Although Sild did not change plasma NOx with respect to untreated hypoxic rats, plasma NOx was higher than in normoxia.

Myocardial Morphology

Myocardial hypertrophy was evaluated through the heart weight/body weight (HW/BW). Hypoxia markedly increased the HW/BW ratio (Figure 3A). This increase was at least in part due to RV hypertrophy, which was evaluated through the RV/(LV+S) ratio (Figure 3B). The increase in both myocardial and RV hypertrophy was mitigated by all treatments, while Mols did not apparently affect the RV/(LV+S) ratio.

Myocardial fibrosis was evaluated separately in the RV and LV by Sirius Red Staining (Figure 4). Hypoxia increased...
myocardial fibrosis in both the LV and RV. All treatments could normalize myocardial fibrosis.

**Biochemistry**

The degree of apoptosis was evaluated through the activation of Caspase-3, a hallmark of apoptosis in myocardial cells (Figure 5A). Hypoxia determined a marked increase in myocardial apoptosis. Myocardial cGMP, which is directly related to the modulation of PDE5 by its inhibitors, was not affected by hypoxia (Figure 5B). The level of myocardial NOx remained nearly unaffected by hypoxia, but all treatments elevated this level with respect to control groups (Figure 5C).

All treatments were able to normalize apoptosis in hypoxia-challenged hearts. By contrast, the myocardial cGMP level was increased only by Sild, as a result of its function as PDE5 inhibitor. All treatments increased the production of NO.

**Hemodynamics**

Hemodynamics was assessed by left and right heart catheterization with measure of the end-diastolic (EDP) and systolic (SP) pressures, and of the rate of pressure development (dP/dt\text{max}). Hypoxia did not affect the left heart function (Figure 6A), but RV SP (Figure 6B) and RV dP/dt\text{max} were markedly increased (Figure 6C), indicative of pulmonary pressure increase. RV EDP remained unaffected (Figure 6C). LV SP was not affected by none of the treatments. By contrast, all treatments decreased RV SP and RV +dP/dt\text{max} (Figure 6D) without effects on RV EDP. All hemodynamics parameters were recorded in rats breathing the same gas mixture, hypoxic or normoxic, to which they were exposed during the preceding 14 days using a technology that fully prevents any risk of reoxygenation.14,15

**Pulmonary Remodeling**

The lung water content highlights the presence of pulmonary edema, which was not affected by hypoxia (Figure 7A). To evaluate pulmonary remodeling, we measured the number of vessels in lung sections stained with hematoxylin & eosin (Figure 7B), as well as the medial wall thickness in large (100-200 μm internal diameter, Figure 7D) and small (internal diameter 0-50 μm, Figure 7E) pulmonary vessels. The figure reports the number of vessels in the left lung only because this value was superimposable to that found in the right lung (not shown).
Figure 5. Effects of hypoxia (14 days at 10% O₂) on myocardial biochemistry in rats treated with placebo (control), L-arginine (L-Arg), molsidomine (Mols), and sildenafil (Sild) for the same time duration. Panels A, B, and C report the effects on Caspase 3, myocardial cGMP content, and the myocardial NOx level, respectively. Data are expressed as box and whiskers plots following the Tukey method, with outliers plotted individually when present. *P < 0.05: normoxia vs hypoxia within the same treatment (Sidak’s test); §P < 0.05: with respect to control within normoxia or hypoxia (Dunnett’s test).

Figure 6. Effects of hypoxia (14 days at 10% O₂) on hemodynamics and myocardial function in rats treated with placebo (control), L-arginine (L-Arg), molsidomine (Mols), and sildenafil (Sild) for the same time duration. Panels A, B, C, and D report the effects on the left ventricle systolic pressure, the right ventricle systolic pressure, the right ventricle end-diastolic pressure, and the maximal rate of pressure development in the right ventricle, respectively. Data are expressed as box and whiskers plots following the Tukey method, with outliers plotted individually when present. *P < 0.05 normoxia vs hypoxia within the same treatment (Sidak’s test); §P < 0.05 with respect to control within normoxia or hypoxia (Dunnett’s test).
Hypoxia markedly increased the number of vessels in the left lung as well as the medial wall thickness of small pulmonary arteries, while pulmonary vessels of larger caliber remained unaffected, confirming previously published data. The effect of the treatments was heterogeneous. While the lung water content remained unchanged, the number of vessels in the left lung was unaffected by Sild, but L-Arg and Mols further increased it. The wall thickness in small vessels was almost normalized by all the treatments, as opposed to lack of effect in large vessels.

Discussion

In this study, we investigate 3 of the broad mechanisms that enhance the NO-cGMP pathway activity in hearts and lungs challenged by chronic hypoxia. As expected, 14-day breathing a gas mixture containing 10% O₂, equivalent to approximately 5000 m altitude, affects most of the considered parameters without being lethal. The degree of hypoxia can therefore be classified as moderate, but still potentially harmful. Therefore, the selected hypoxia condition results in a layout that includes depressed body homeostasis, excessive erythropoiesis, heart and RV hypertrophy, myocardial fibrosis, higher degree of apoptosis and as a stimulus for pulmonary vascular remodeling. These features lead to a phenotype very similar to PH in humans. As drug treatments started in coincidence with the onset of hypoxia, the observed mechanisms may reflect prophylactic rather than therapeutic interventions.

The stimulation of anyone of the 3 broad mechanisms that enhance the NO-cGMP pathway did not produce appreciable changes in normoxia, but tended to improve, and in some instance to normalize most of the parameters that were challenged by hypoxia. This highlights the validity of the experimental model with respect to the pathological situation of PH patients. Remarkably, monocrotaline-treated rats, a common rodent model of PH, develop symptoms similar to those elicited by hypoxia only, including pulmonary vessel remodeling, RV hypertrophy and apoptosis. However, hypoxia-induced PH occurs without use of compounds that were reviewed to be subjected to differences in pharmacokinetics, hepatic...
formation of pyrrole derivatives that finally lead to anorexia, apathy, inability to gain weight and tachypnea, all symptoms that may overlap with those led by hypoxia as dyspnea, weakness, diarrhea, and peripheral cyanosis. In addition to monocrotaline-treated rats, the Sugen/Hypoxia model also mimics PAH in group 1 by combining a single administration of Sugen 5416, a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, with 3-week hypoxia. This treatment causes severe PAH in rats, characterized by smooth muscle proliferation, vascular rarefaction and perivascular fibrosis that contribute to increase precapillary vascular resistance, RV afterload and hypertrophy even after return to normoxia for 5-10 weeks. Compared with rats exposed to chronic hypoxia alone, Su-Hx rats develop decompensated RV failure, as evident from elevated RV EDP, RV dilatation and decreased RV ejection fraction with maladaptive RV remodeling. A third PH model is constituted by the persistent PH model obtainable in lambs by surgical constriction of the fetal ductus arteriosus, which results in increased right-to-left extra-pulmonary shunting of deoxygenated blood and mimics with augmented vascular constriction and smooth muscle hypertrophy, which leads to persistently increased pulmonary vascular resistance and RV hypertrophy.

In this study, rats were exposed to hypoxia for 14 days, a time long enough to rise some adaptation to hypoxia or compensation to PH. Therefore, data taken at a single time point may be considered potentially unstable and not fully representative of hypoxia-induced PH. However, we previously showed that in this model most of the data reported here remain constant for 4 weeks. Despite ongoing hypoxia adaption as from the steadily increasing erythropoietic response, most parameters related to the compensation to PH appear relatively constant, including the RV/(LV+S) ratio, the number of lung vessels, the wall thickness of small vessels, RV fibrosis, and myocardial NOx. Remarkably, the effect of one of the interventions described here, e.g. PDE5 inhibition, elicits similar myocardial NOx. Remarkably, the effect of one of the interventions described here, e.g. PDE5 inhibition, elicits similar myocardial NOx. Remarkably, the effect of one of the interventions described here, e.g. PDE5 inhibition, elicits similar myocardial NOx. Remarkably, the effect of one of the interventions described here, e.g. PDE5 inhibition, elicits similar myocardial NOx. Remarkably, the effect of one of the interventions described here, e.g. PDE5 inhibition, elicits similar myocardial NOx. Remarkably, the effect of one of the interventions described here, e.g. PDE5 inhibition, elicits similar myocardial NOx. Furthermore, the selected dose of Mols (15 mg/kg/day) compares with that associated with improved resting systolic blood pressure and quality of life in PH patients with microvascular angina (0.1 g/kg/day for 4 weeks). Similar doses were also effective to improve hemodynamics and exercise capacity in patients with precapillary PH (up to 0.15 g/kg) as well as to ameliorate functional and quality of life outcomes (0.1 g/kg/day for 3 months). Likewise, the selected dose of Mols (15 mg/kg/day) compares with that reported in the MEDCOR clinical trial demonstrating beneficial effects on the myeloperoxidase activity/antigen ratio in angina patients undergoing percutaneous coronary intervention (16 mg/day for 1 year) and is identical to that reported to be effective to reduce PH in hypoxic rats.

As for Sild, the typical per os dose used for PAH treatment is usually higher (25-100 mg/kg twice-daily per os) than that used in the present
study. However, for consistency with previous studies, we opted for i.p. delivery of Sild in a single daily dose within the range that saturates protection in humans. Despite the plasma half-life of 4-6 h, the selected dose was observed to elevate myocardial cGMP in a rodent model of hypoxia, indicative of efficient inhibition of PDE5 activity. Other agents such as the stimulator of sGC riociguat might soon be competitive. This consideration is further supported by the observation that deactivating by oxidation the α subunit of protein kinase G does not change the benefits of the stimulation of sGC, thereby highlighting the combination therapy with PDE5 inhibitors and sGC stimulators. Here we show that the effect of Sild is virtually indistinguishable from those of L-Arg and Mols, with a slight improvement of body homeostasis. As expected, Sild did not affect the parameters upstream PDE5 inhibition, e.g. neither plasma nor myocardial NOx.

**Limitations of the Study**

In this study, no attempt was made to compare directly the effectiveness of the 3 strategies to improve the NO-cGMP pathway. This goal should be preceded by complex pharmacokinetic evaluations as well as dose/response preliminary studies. Likewise, a large number of drugs and approaches were not examined in this study, but we focused in a representative drug for every site of modulation. As far as NO donors are considered, alternative drugs/treatments include inhaled NO therapy, administration of inorganic nitrite and nitrate, such as sodium nitrite, as well as diethylamine NONOate diethylammonium, sodium nitroprusside and the sGC stimulator riociguat. As for PDE5 inhibitors, several other drugs besides Sild have been proposed, each with different pharmacokinetics, efficiency and persistence in the circulation, but with essentially similar mechanisms of action and outcomes. Finally, in this study we did not assess any combination of these approaches in the search of synergistic effects.

**Conclusion**

Enhancing the NO-cGMP pathway in any form attenuates the hypoxia-related PH syndrome. Remarkably, the tested treatments appeared to be effective in hypoxia at doses that were ineffective in normoxia. Thus, the 3 strategies to enhance the NO-cGMP pathway in vivo appear equivalent in terms of efficacy and molecular mechanisms of action. The choice of the best treatment, therefore, should not be based on the mechanisms of action but rather on clinical relevance, such as tolerability, side effects and persistence in the circulation.

---

**Table 1. Summary of the Observed Findings.**

|                          | Hypoxia vs normoxia | l-Arginine | Molsidomine | Sildenafil |
|--------------------------|---------------------|------------|-------------|------------|
| **Systemic changes**     | Body homeostasis    | ↓          | =           | =          | ↑          |
| Erythropoiesis           | ↑                   | =          | =           | ↑          |
| Plasma nitrates + nitrites | =                 | =          | ↑           | =          |
| **Myocardial morphology**| Cardiac hypertrophy | ↑          | ↓           | ↓          | ↓          | N          |
| RV hypertrophy           | ↑                   | ↓           | =           | ↑          |
| LV fibrosis              | ↑                   | ↑↓          | =           | ↑          |
| RV fibrosis              | ↑                   | ↑↓          | ↑↓          | ↑↓         |
| **Heart biochemistry**   | Caspase-3 activation| ↑          | ↓↓          | ↓↓         | ↓↓         |
| Heart cGMP               | =                   | =          | =           | ↑          |
| Myocardial NOx           | =                   | ↑↑         | ↑↑          |
| **Myocardial function**  | LV systolic pressure| =         | =           | =          | =          |
| RV systolic pressure     | ↑                   | ↓↓         | ↓↓          | ↓↓         |
| RV end-diastolic pressure| =                   | =          | =           | =          |
| RV +dP/dt<sub>max</sub>  | ↑                   | ↓↓         | ↓↓          | ↓↓         |
| **Pulmonary remodeling** | Lung hypertrophy    | ↑          | =           | =          | =          |
| Pulmonary remodeling, small vessels (<50 μm) | ↑   | ↓↓         | ↓↓         | ↓↓         |
| Pulmonary remodeling, large vessels (100-200 μm) | = | = | = | = |

*a*, increase; ↓, decrease; =, no change. For within hypoxia: ↑↑ and ↑↑ mean complete normalization (decrease or decrease, respectively) with respect to normoxia control. N denotes that the effect was observed also in normoxia.
Acknowledgments

The authors acknowledge the support by the Swiss National Foundation and the Department of Health Science, University of Milan, Italy.

Author Contributions

Conceptualization, M.B., M.S., G.M., L.K.V.S.; methodology, M.R., G.M.; formal analysis, M.S.; investigation, M.B., G.M.; resources, P.T., L.K.V.S.; data curation, M.R., G.M.; writing-original draft preparation, M.S., G.M.; writing-review and editing, M.B., P.T.; project administration, P.T., L.K.V.S.; funding acquisition, P.T., G.M., L.K.V.S. All authors have read and agreed to the published version of the manuscript.

Declaration of Conflicting Interests

The author(s) declared receipt of the following financial support for the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Received support from the Swiss National Foundation (FN 310000-110058 to G.M.) and the Department of Health Science, University of Milan (Piano Sostegno Ricerca PSR2019_DIP_013 to M.S.).

ORCID iDs

Maurice Beghetti https://orcid.org/0000-0002-1841-0927
Giuseppina Milano https://orcid.org/0000-0002-4554-9465

References

1. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115-130.
2. Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol. 2007;27(9):1877-1885.
3. Budhiraja R, Tudor RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159-165.
4. Klinger JR, Kadowitz PJ. The nitric oxide pathway in pulmonary vascular disease. Am J Cardiol. 2017;120(8S):S71-S9.
5. Palmer R, Ashton D, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
6. Gladwin M, Ognibene F, Pannell L, et al. Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation. Proc Natl Acad Sci USA. 2000;97:9943-9948.
7. Murad F, Leitman DC, Bennett BM, Molina C, Waldman SA. Regulation of guanylate cyclase by atrial natriuretic factor and the role of cyclic GMP in vasodilation. Am J Med Sci. 1987;294(3):139-143.
8. Sarkar D, Vallance P, Harding SE. Nitric oxide: not just a negative inotrope. Eur J Heart Fail. 2001;3(5):527-534.
9. Kuroda K, Akagi S, Nakamura K, Sarashina T, Ejiri K, Ito H. Successful transition from phosphodiesterase-5 inhibitors to riociguat without a washout period in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a pilot cohort study. Heart Lung Circ. 2020;29(3):331-336.
10. Dillard J, Perez M, Chen B. Therapies that enhance pulmonary vascular NO-signaling in the neonate. Nitric Oxide. 2020;95:45-54.
11. Bath PM, Krishnan K, Appleton JP. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochrane Database Syst Rev. 2017;4:CD000398.
12. Nydegger C, Corno AF, von Segesser LK, Beghetti M, Samaja M, Milano G. Effects of PDE-5 inhibition on the cardiac pulmonary system after 2 or 4 weeks of chronic hypoxia. Cardiovasc Drugs Ther. 2019;33(4):407-414.
13. Nydegger C, Martinelli C, Di Marco F, et al. Phosphodiesterase-5 inhibition alleviates pulmonary hypertension and basal lamina thickening in rats challenged by chronic hypoxia. Front Physiol. 2018;9:289.
14. Milano G, Corno AF, Lippa S, Von Segesser LK, Samaja M. Chronic and intermittent hypoxia induce different degrees of myocardial tolerance to hypoxia-induced dysfunction. Exp Biol Med (Maywood). 2002;227(6):389-397.
15. Milano G, Abruzzo PM, Bolotta A, et al. Impact of the phosphatidylinositol 3-kinase signaling pathway on the cardioprotection induced by intermittent hypoxia. PloS One. 2013;8(10):e76659.
16. Favre S, Gambini E, Nigro P, et al. Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells. J Cell Mol Med. 2017;21(5):871-880.
17. Bello-Klein A, Mancardi D, Araujo AS, Schenkel PC, Turck P, de Lima Seolin BG. Role of redox homeostasis and inflammation in the pathogenesis of pulmonary arterial hypertension. Curr Med Chem. 2018;25(11):1340-1351.
18. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15(2):427-438.
19. Abe K, Toba M, Alzoubi A, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010;121(25):2747-2754.
20. Legchenko E, Chouvarine P, Borchert P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018;10(438):eaao0303.
21. Teng RJ, Du J, Welak S, et al. Cross talk between NADPH oxidase and autophagy in pulmonary artery endothelial cells with intrauterine persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;302(7):L651-L663.
22. Ke X, Johnson H, Jing X, et al. Persistent pulmonary hypertension alters the epigenetic characteristics of endothelial nitric oxide synthase gene in pulmonary artery endothelial cells in a fetal lamb model. Physiol Genomics. 2018;50(10):828-836.
23. Sandqvist A, Schneede J, Kylhammar D, et al. Plasma L-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction. Heart Vessels. 2018;33(3):255-263.
24. Ou ZJ, Wei W, Huang DD, et al. L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. Am J Physiol Endocrinol Metab. 2010;298(6):E1131-E1139.
25. Howell K, Costello CM, Sands M, Dooley I, McLoughlin P. L-Arginine promotes angiogenesis in the chronically hypoxic...
lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296(6):L1042-L1050.

26. Morris CR, Morris SM Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168(1):63-69.

27. Dikalova A, Aschner JL, Kaplowitz MR, Cunningham G, Summar M, Fike CD. Combined L-citrulline and tetrahydrobiopterin therapy improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension in newborn pigs. Am J Physiol Lung Cell Mol Physiol. 2020;318(4):L762-L772.

28. Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med. 2011;50(7):765-776.

29. Maxwell AJ. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide. 2002;6(2):101-124.

30. Loskove JA, Frishman WH. Nitric oxide donors in the treatment of cardiovascular and pulmonary diseases. Am J Heart. 1995;129(3):604-613.

31. Alanova P, Kolar F, Ostadal B, Neckar J. Role of NO/cGMP signaling pathway in cardiac ischemic tolerance of chronically hypoxic rats. Physiol Res. 2015;64(5):783-787.

32. Mathew R, Gloster ES, Sundararajan T, Thompson CI, Zeballos P. Combined L-citrulline and tetrahydrobiopterin therapy improves NO signaling and ameliorates chronic hypoxia-induced pulmonary hypertension: combined administration with inhaled nitric oxide. Lung: a novel mechanism ameliorating pulmonary hypertension. Am J Cardiol. 2002;90(6):677-680.

33. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169(1):39-45.

34. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127(5):1647-1653.

35. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104(4):424-428.

36. Lyons JM, Duffy JY, Wagner CJ, Pearl JM. Sildenafil citrate alleviates pulmonary hypertension after hypoxia and reoxygenation with cardiopulmonary bypass. J Am Coll Surg. 2004;199(4):607-614.

37. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5(8):689-702.

38. Pallosi A, Fragasso G, Piatti P, et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol. 2004;93(7):933-935.

39. Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 2001;163(4):887-891.

40. Brown MB, Kempf A, Collins CM, et al. A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study. Palm Circ. 2018;8(1):204589217743966.

41. Barbato E, Herman A, Benit E, et al. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial. Atherosclerosis. 2015;240(2):351-354.

42. Andersen CU, Mulvany MJ, Simonsen U. Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. Eur J Pharmacol. 2005;510(1-2):87-96.

43. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83(5A):13C-20C.

44. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47-52.

45. Beghetti M, Gorenflo M, Ivy DD, Moledina S, Bonnet D. Treatment of pediatric pulmonary arterial hypertension: a focus on the NO-sGC-cGMP pathway. Pulm Circ. 2018;8(1):e004740.

46. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169(1):39-45.

47. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest. 2005;127(5):1647-1653.
57. Hunter CJ, Dejam A, Blood AB, et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. *Nat Med.* 2004;10(10):1122-1127.

58. Munzel T, Daiber A. Inorganic nitrite and nitrate in cardiovascular therapy: a better alternative to organic nitrates as nitric oxide donors? *Vascul Pharmacol.* 2018;102:1-10.

59. Jankov RP, Daniel KL, Iny S, et al. Sodium nitrite augments lung S-nitrosylation and reverses chronic hypoxic pulmonary hypertension in juvenile rats. *Am J Physiol Lung Cell Mol Physiol.* 2018;315(5):L742-L751.

60. Mondejar-Parreno G, Moral-Sanz J, Barreira B, et al. Activation of Kv 7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation. *Br J Pharmacol.* 2019;176(13):2131-2145.

61. Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. *Cochrane Database Syst Rev.* 2019;1(1):Cd012621.